IMAB 027

Drug Profile

IMAB 027

Alternative Names: IMAB027

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Ganymed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Claudin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Ovarian cancer

Most Recent Events

  • 21 Dec 2016 Ganymed Pharmaceuticals has been acquired by Astellas Pharma
  • 17 May 2016 Ganymed completes a phase I part of the phase I/II trial in Ovarian cancer (Late-stage disease) in Belgium, Germany, Russia and Ukraine
  • 17 May 2016 Ganymed intends to initiate a phase II part of the phase I/II trial for Ovarian cancer (Late-stage disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top